Gevel-M 1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The prolonged-release formulation of Gevel-M 1 Forte ensures a sustained therapeutic effect, promoting better glycemic control with once-daily dosing, which may improve patient compliance. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Gevel-M 1 Forte should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose and HbA1c levels. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with diabetic ketoacidosis or severe renal dysfunction. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Regular follow-up is essential to adjust dosage and monitor for potential side effects and therapeutic efficacy.